157 related articles for article (PubMed ID: 35379077)
21. Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients.
Mangaonkar AA; Lasho TL; Ketterling RP; Reichard KK; Gangat N; Al-Kali A; Begna KH; Pardanani A; Al Ali NH; Talati C; Sallman D; Padron E; Patnaik MM; Tefferi A; Komrokji R
Blood Cancer J; 2022 Feb; 12(2):26. PubMed ID: 35105856
[TBL] [Abstract][Full Text] [Related]
22. [Genomic aberrations in myelodysplastic syndromes and related disorders].
Makishima H
Rinsho Ketsueki; 2019; 60(6):600-609. PubMed ID: 31281151
[TBL] [Abstract][Full Text] [Related]
23. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms.
Wang SA; Hasserjian RP; Fox PS; Rogers HJ; Geyer JT; Chabot-Richards D; Weinzierl E; Hatem J; Jaso J; Kanagal-Shamanna R; Stingo FC; Patel KP; Mehrotra M; Bueso-Ramos C; Young KH; Dinardo CD; Verstovsek S; Tiu RV; Bagg A; Hsi ED; Arber DA; Foucar K; Luthra R; Orazi A
Blood; 2014 Apr; 123(17):2645-51. PubMed ID: 24627528
[TBL] [Abstract][Full Text] [Related]
24. Panel-based gene testing in myelodysplastic/myeloproliferative neoplasm overlap syndromes: Australasian Leukaemia and Lymphoma Group (ALLG) consensus statement.
Enjeti AK; Agarwal R; Blombery P; Chee L; Chua CC; Grigg A; Hamad N; Iland H; Lane S; Perkins A; Singhal D; Tate C; Tiong IS; Ross DM
Pathology; 2022 Jun; 54(4):389-398. PubMed ID: 35461716
[TBL] [Abstract][Full Text] [Related]
25. Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T) - "2021 update on diagnosis, risk-stratification, and management".
Patnaik MM; Tefferi A
Am J Hematol; 2021 Mar; 96(3):379-394. PubMed ID: 33428785
[TBL] [Abstract][Full Text] [Related]
26. Myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): More than just a "catch-all" term?
Shallis RM; Zeidan AM
Best Pract Res Clin Haematol; 2020 Jun; 33(2):101132. PubMed ID: 32460977
[TBL] [Abstract][Full Text] [Related]
27. Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients.
Coston T; Pophali P; Vallapureddy R; Lasho TL; Finke CM; Ketterling RP; Carr R; Binder M; Mangaonkar AA; Gangat N; Al-Kali A; Litzow M; Zblewski D; Pardanani A; Tefferi A; Patnaik MM
Am J Hematol; 2019 Jul; 94(7):767-779. PubMed ID: 30964202
[TBL] [Abstract][Full Text] [Related]
28. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.
Malcovati L; Papaemmanuil E; Bowen DT; Boultwood J; Della Porta MG; Pascutto C; Travaglino E; Groves MJ; Godfrey AL; Ambaglio I; Gallì A; Da Vià MC; Conte S; Tauro S; Keenan N; Hyslop A; Hinton J; Mudie LJ; Wainscoat JS; Futreal PA; Stratton MR; Campbell PJ; Hellström-Lindberg E; Cazzola M;
Blood; 2011 Dec; 118(24):6239-46. PubMed ID: 21998214
[TBL] [Abstract][Full Text] [Related]
29. Surveying the landscape of MDS/MPN research: overlap among the overlap syndromes?
Padron E
Hematology Am Soc Hematol Educ Program; 2015; 2015():349-54. PubMed ID: 26637742
[TBL] [Abstract][Full Text] [Related]
30. Myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis: Ringing in a new future.
Nathan DI; Feld J; El Jamal SM; Mascarenhas J; Tremblay D
Leuk Res; 2022 Apr; 115():106820. PubMed ID: 35279478
[TBL] [Abstract][Full Text] [Related]
31. An Exercise in Extrapolation: Clinical Management of Atypical CML, MDS/MPN-Unclassifiable, and MDS/MPN-RS-T.
Talati C; Padron E
Curr Hematol Malig Rep; 2016 Dec; 11(6):425-433. PubMed ID: 27664113
[TBL] [Abstract][Full Text] [Related]
32. Validation of Molecular International Prognostic Scoring System (IPSS-M) in myelodysplastic/myeloproliferative neoplasms, not otherwise specified (MDS/MPN-NOS).
Mangaonkar AA; Swoboda DM; Lasho TL; Finke C; Ketterling RP; Reichard KK; Komrokji R; Padron E; Patnaik MM
Leuk Res; 2023 Aug; 131():107340. PubMed ID: 37356165
[No Abstract] [Full Text] [Related]
33. Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia.
Malcovati L; Papaemmanuil E; Ambaglio I; Elena C; Gallì A; Della Porta MG; Travaglino E; Pietra D; Pascutto C; Ubezio M; Bono E; Da Vià MC; Brisci A; Bruno F; Cremonesi L; Ferrari M; Boveri E; Invernizzi R; Campbell PJ; Cazzola M
Blood; 2014 Aug; 124(9):1513-21. PubMed ID: 24970933
[TBL] [Abstract][Full Text] [Related]
34. Clinical analysis and literature review of a case with the myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis.
Long B; Shi H; Zhu C
Hematology; 2020 Dec; 25(1):283-285. PubMed ID: 32657243
[No Abstract] [Full Text] [Related]
35. Myeloproliferative neoplasms (BCR-ABL1 negative) and myelodysplastic/myeloproliferative neoplasms: current diagnostic principles and upcoming updates.
Geyer JT; Orazi A
Int J Lab Hematol; 2016 May; 38 Suppl 1():12-9. PubMed ID: 27161873
[TBL] [Abstract][Full Text] [Related]
36. A Pilot Clinical Study to Investigate the Hypomethylating Properties of Freeze-dried Black Raspberries in Patients with Myelodysplastic Syndrome or Myeloproliferative Neoplasm.
Dong A; Pan X; Lin CW; Huang YW; Krause H; Pan P; Baim A; Thomas MJ; Chen X; Yu J; Michaelis L; Liu P; Wang LS; Atallah E
J Cancer Prev; 2022 Jun; 27(2):129-138. PubMed ID: 35864858
[TBL] [Abstract][Full Text] [Related]
37. Many faces of SF3B1-mutated myeloid neoplasms: concurrent mutational profiles contribute to the diverse clinical and morphologic features.
Aqil B; Sukhanova M; Behdad A; Jennings L; Lu X; Chen Q; Chen YH; Gao J
Hum Pathol; 2022 Nov; 129():81-89. PubMed ID: 36087739
[TBL] [Abstract][Full Text] [Related]
38. A phase 2 trial of combination therapy with thalidomide, arsenic trioxide, dexamethasone, and ascorbic acid (TADA) in patients with overlap myelodysplastic/myeloproliferative neoplasms (MDS/MPN) or primary myelofibrosis (PMF).
Bejanyan N; Tiu RV; Raza A; Jankowska A; Kalaycio M; Advani A; Chan J; Saunthararajah Y; Mooney L; Maciejewski JP; Sekeres MA
Cancer; 2012 Aug; 118(16):3968-76. PubMed ID: 22180010
[TBL] [Abstract][Full Text] [Related]
39. Exploring blast composition in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms: CD45RA and CD371 improve diagnostic value of flow cytometry through assessment of myeloblast heterogeneity and stem cell aberrancy.
Shameli A; Dharmani-Khan P; Luider J; Auer I; Shabani-Rad MT
Cytometry B Clin Cytom; 2021 Sep; 100(5):574-589. PubMed ID: 33369070
[TBL] [Abstract][Full Text] [Related]
40. Progression, transformation, and unusual manifestations of myelodysplastic syndromes and myelodysplastic-myeloproliferative neoplasms: lessons learned from the XIV European Bone Marrow Working Group Course 2019.
Hebeda K; Boudova L; Beham-Schmid C; Orazi A; Kvasnicka HM; Gianelli U; Tzankov A
Ann Hematol; 2021 Jan; 100(1):117-133. PubMed ID: 33128619
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
